UCB Provides Synosia With Its First Out-Licensing Deal And Leads Its $30M Series C Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB gains rights to Synosia's potential Parkinson's disease therapies in deal that could be worth $725 million in milestones
You may also be interested in...
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.
Biotie To Combine With Synosia To Form A "Global Leader" In CNS Drug Development
A Phase III drug for alcohol dependence and two Parkinson's disease therapies will head the pipeline of a proposed new European CNS drug development company.